NCT03158792

Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function

Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Lebanese American University · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

This is a clinical trial including non-surgical patients, 70 years of age or older, with renal impairment requiring pharmacological venous thromboembolism prevention during hospitalization. Patients are randomized to receive either 20 mg or 30mg of enoxaparin. Both dosing regimens of enoxaparin have been approved for thromboprophylaxis in impaired kidney function in different countries. Therefore, this study aims to evaluate the efficacy and safety of enoxaparin 20mg versus 30mg subcutaneously daily by comparing anti-xa levels, thrombosis and bleeding events.

Conditions

• Venous Thromboembolism
• Renal Impairment

Interventions

Type	Name	Description
DRUG	Enoxaparin 20Mg/0.2mL Prefilled Syringe	Enoxaparin 20mg subcutaneously once daily
DRUG	Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml	Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered

Timeline

• Start date: 2015-10-24
• Primary completion: 2017-07-13
• Completion: 2017-07-13
• First posted: 2017-05-18
• Last updated: 2017-09-11

Locations

1 site across 1 country: Lebanon